5 Most Promising Gene Therapy Companies to Watch

2. Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Market Capitalization as of November 12, 2022: $4.32 billion

Intellia Therapeutics, Inc. (NASDAQ:NTLA) develops treatments for liver diseases, leukemia, cancers, and autoimmune disorders. The firm was set up in 2014 and is headquartered in Cambridge, Massachusetts.

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is aiming to become an all out player in the gene editing sector, and the firm took a bold move earlier this year when it acquired another firm for a whopping $200 million. While acquisitions are common play in the business world, it is highly uncommon for a research focused firm with limited finances to make such a move. The deal will let Intellia Therapeutics, Inc. (NASDAQ:NTLA) expand its treatments beyond diseases of the eyes and liver, and diversify its gene editing portfolio to other areas as well.

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has a $4.32 billion market capitalization.

Catherine D. Wood’s ARK Investment Management is Intellia Therapeutics, Inc. (NASDAQ:NTLA)’s largest investor. It owns 9.5 million shares that are worth $439 million.

Follow Intellia Therapeutics Inc. (NASDAQ:NTLA)